Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(2):266–269. doi: 10.1038/bjc.1997.374

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.

C J Punt 1, C M van Herpen 1, R L Jansen 1, G Vreugdenhil 1, E W Muller 1, P H de Mulder 1
PMCID: PMC2223935  PMID: 9231931

Abstract

High response rates in patients with metastatic melanoma have been achieved with combination chemoimmunotherapy. A response rate of 62% in 45 patients has been reported for treatment with dacarbazine, bleomycin, vincristine, lomustine (BOLD) plus interferon alpha (IFN-alpha). We conducted a multicentre phase II study to confirm these results. Melanoma patients with distant metastases were treated as outpatients with dacarbazine 200 mg m(-2) on days 1-5, vincristine 1 mg m(-2) on days 1 and 4, bleomycin 15 mg on days 2 and 5 i.v. and lomustine 80 mg orally on day 1, repeated every 4 weeks. IFN-alpha-2b was initiated s.c. on day 8 at 3 MU daily for 6 weeks, and 6 MU t.i.w. thereafter. Forty-three patients entered the study. The median number of metastatic sites was three (range 1-5), and 81% of patients had visceral metastases. Nine patients had brain metastases, and seven patients were systemically pretreated. Among the 41 patients that were evaluable for response, the response rate was 27% (95% CI 14-3%), with one complete and ten partial remissions. The response rate in 25 previously untreated patients without brain metastases was 40% (95% CI 21-61%). Median duration of response was 6 (range 2-14+) months; median overall survival was 5 (1-26) months. The main toxicity was malaise/fatigue. We confirm that BOLD plus IFN-alpha has activity in metastatic melanoma. The lower response rate in our study compared with the previous report is probably related to patient selection, as in the previous study 46% of patients had stage III disease, whereas all our patients had stage IV disease, which is associated with a worse prognosis.

Full text

PDF
266

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkins M. B., O'Boyle K. R., Sosman J. A., Weiss G. R., Margolin K. A., Ernest M. L., Kappler K., Mier J. W., Sparano J. A., Fisher R. I. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol. 1994 Aug;12(8):1553–1560. doi: 10.1200/JCO.1994.12.8.1553. [DOI] [PubMed] [Google Scholar]
  2. Bajetta E., Di Leo A., Zampino M. G., Sertoli M. R., Comella G., Barduagni M., Giannotti B., Queirolo P., Tribbia G., Bernengo M. G. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol. 1994 Apr;12(4):806–811. doi: 10.1200/JCO.1994.12.4.806. [DOI] [PubMed] [Google Scholar]
  3. Buzaid A. C., Legha S. S. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. Semin Oncol. 1994 Dec;21(6 Suppl 14):23–28. [PubMed] [Google Scholar]
  4. Cantell K., Hirvonen S., Koistinen V. Partial purification of human leukocyte interferon on a large scale. Methods Enzymol. 1981;78(Pt A):499–505. doi: 10.1016/0076-6879(81)78161-8. [DOI] [PubMed] [Google Scholar]
  5. Del Prete S. A., Maurer L. H., O'Donnell J., Forcier R. J., LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep. 1984 Nov;68(11):1403–1405. [PubMed] [Google Scholar]
  6. Falkson C. I., Falkson G., Falkson H. C. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol. 1991 Aug;9(8):1403–1408. doi: 10.1200/JCO.1991.9.8.1403. [DOI] [PubMed] [Google Scholar]
  7. Fiedler W., Jasmin C., De Mulder P. H., Pyrhönen S., Palmer P. A., Franks C. R., Oskam R., Hossfeld D. K. A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma. Eur J Cancer. 1992;28(2-3):443–446. doi: 10.1016/s0959-8049(05)80073-5. [DOI] [PubMed] [Google Scholar]
  8. Hernberg M., Muhonen T., Turunen J. P., Hahka-Kemppinen M., Pyrhönen S. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy. J Clin Oncol. 1996 May;14(5):1690–1696. doi: 10.1200/JCO.1996.14.5.1690. [DOI] [PubMed] [Google Scholar]
  9. Karakousis C. P., Emrich L. J., Rao U. Groin dissection in malignant melanoma. Am J Surg. 1986 Nov;152(5):491–495. doi: 10.1016/0002-9610(86)90211-4. [DOI] [PubMed] [Google Scholar]
  10. Khayat D., Borel C., Tourani J. M., Benhammouda A., Antoine E., Rixe O., Vuillemin E., Bazex P. A., Thill L., Franks R. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol. 1993 Nov;11(11):2173–2180. doi: 10.1200/JCO.1993.11.11.2173. [DOI] [PubMed] [Google Scholar]
  11. Kruit W. H., Punt C. J., Goey S. H., de Mulder P. H., Gratama J. W., Eggermont A. M., Bolhuis R. L., Stoter G. Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma. Br J Cancer. 1996 Sep;74(6):951–955. doi: 10.1038/bjc.1996.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kruit W. H., Punt K. J., Goey S. H., de Mulder P. H., van Hoogenhuyze D. C., Henzen-Logmans S. C., Stoter G. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication. Cancer. 1994 Nov 15;74(10):2850–2856. doi: 10.1002/1097-0142(19941115)74:10<2850::aid-cncr2820741018>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  13. Legha S. S., Ring S., Papadopoulos N., Plager C., Chawla S., Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989 Nov 15;64(10):2024–2029. doi: 10.1002/1097-0142(19891115)64:10<2024::aid-cncr2820641010>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  14. Marincola F. M., White D. E., Wise A. P., Rosenberg S. A. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol. 1995 May;13(5):1110–1122. doi: 10.1200/JCO.1995.13.5.1110. [DOI] [PubMed] [Google Scholar]
  15. McClay E. F., Mastrangelo M. J., Berd D., Bellet R. E. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer. 1992 Feb 20;50(4):553–556. doi: 10.1002/ijc.2910500410. [DOI] [PubMed] [Google Scholar]
  16. Mulder N. H., van der Graaf W. T., Willemse P. H., Koops H. S., de Vries E. G., Sleijfer D. T. Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma. Br J Cancer. 1994 Oct;70(4):681–683. doi: 10.1038/bjc.1994.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pyrhönen S., Hahka-Kemppinen M., Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol. 1992 Dec;10(12):1919–1926. doi: 10.1200/JCO.1992.10.12.1919. [DOI] [PubMed] [Google Scholar]
  18. Richards J. M., Mehta N., Ramming K., Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992 Aug;10(8):1338–1343. doi: 10.1200/JCO.1992.10.8.1338. [DOI] [PubMed] [Google Scholar]
  19. Seigler H. F., Lucas V. S., Jr, Pickett N. J., Huang A. T. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer. 1980 Dec 1;46(11):2346–2348. doi: 10.1002/1097-0142(19801201)46:11<2346::aid-cncr2820461104>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  20. Stoter G., Aamdal S., Rodenhuis S., Cleton F. J., Iacobelli S., Franks C. R., Oskam R., Shiloni E. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol. 1991 Sep;9(9):1687–1691. doi: 10.1200/JCO.1991.9.9.1687. [DOI] [PubMed] [Google Scholar]
  21. Thomson D. B., Adena M., McLeod G. R., Hersey P., Gill P. G., Coates A. S., Olver I. N., Kefford R. F., Lowenthal R. M., Beadle G. F. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res. 1993 Apr;3(2):133–138. [PubMed] [Google Scholar]
  22. York R. M., Foltz A. T. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer. 1988 Jun 1;61(11):2183–2186. doi: 10.1002/1097-0142(19880601)61:11<2183::aid-cncr2820611108>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES